-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
When it comes to weight loss, many people have been "struggling" for many years, dieting, yoga, running, and even some people have taken laxatives
.
However, the reason why you can't lose weight may not be not working hard enough, but that you are suffering from "obesity"! On September 29, Altimmune received good news.
Its glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist pemvidutide (ALT-801) was the first human body to treat obesity.
The positive results obtained in clinical trials may provide a new treatment method for the treatment of obesity
.
Altimmune's official website What is obesity? Specifically, obesity is a chronic metabolic disease caused by a variety of factors.
When the human body eats more calories than consumes calories, the excess calories are stored in the body in the form of fat, which exceeds the normal physiological requirement and reaches a certain level.
It will evolve into obesity when it is worthwhile
.
According to the "Chinese National Health and Nutrition Big Data Report", China has 507 million people with overweight and obesity, ranking first in the world.
Not only that, research in the past ten years has found that obesity can also induce a variety of diseases.
Development occurs, so maintaining a healthy figure is not only for pleasing the eyes, but also to reduce the risk of death
.
Pemvidutide (ALT-801) is a peptide-based GLP-1/glucagon dual receptor agonist, which promotes the conversion of white fat into brown fat in the body to consume energy
.
When it has a synergistic effect with GLP-1, it will have a better effect than using a GLP-1 receptor agonist alone
.
The results of its phase 1 clinical trial showed that after receiving 1.
2 mg, 1.
8 mg, and 2.
4 mg pemvidutide, the weight of obese patients decreased by an average of 4.
9%, 10.
3%, and 9.
0%, respectively
.
It is worth noting that in the patient group who received 1.
8 mg of pemvidutide, 55% of the patients lost more than 10% of their body weight, and all patients lost more than 5% of their body weight
.
The weight loss of patients receiving different doses of pemvidutide is more important, the previous studies have shown that pemvidutide can be injected once a week to make the medication more convenient for patients
.
Not only that, the safety of the drug is good, there are no serious treatment-related adverse events, and there are no reports of termination of the trial due to adverse events
.
In the future, it is expected that this new type of weight loss therapy can solve the problems of obese patients
.
In order to facilitate you to continue to receive our articles, you are welcome to set us as a "star" so that you can see our news in the future
.
End reference materials: [1]https://ir.
altimmune.
com/news-releases/news-release-details/altimmune-announces-positive-results-12-week-phase-1-clinical Heavyweight: This kind of malignant tumor with the highest fatality rate may usher in the era of precision treatment.
Hot text generates hundreds of billions of revenue in 6 months.
Why is mRNA such a "god"? Hot article latest! The "Patient Zero" of the new crown in the United States has a high probability of appearing in the hot article Cell sub-news around September 2019: Create another miracle of life! Scientists use pluripotent stem cells to successfully cultivate artificial sperm, which can produce healthy offspring.
AJCN: To live longer, eat beans often! Long-term consumption of soybean diet can make the brain "more agile".
Medical immunotherapy | Biosimilars | Vaccines | Resistance | Drug targets | Healthy life | Pharmaceutical News | Drug inventory | | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anti-cancer Drugs | 4+7 Volume Procurement | Consumables | Record-filing System | Registrant System | Healthy China | New Edition Essential Medicine List | AI Medical Devices | Telemedicine | Same-share non-equity market/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market |
.
However, the reason why you can't lose weight may not be not working hard enough, but that you are suffering from "obesity"! On September 29, Altimmune received good news.
Its glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist pemvidutide (ALT-801) was the first human body to treat obesity.
The positive results obtained in clinical trials may provide a new treatment method for the treatment of obesity
.
Altimmune's official website What is obesity? Specifically, obesity is a chronic metabolic disease caused by a variety of factors.
When the human body eats more calories than consumes calories, the excess calories are stored in the body in the form of fat, which exceeds the normal physiological requirement and reaches a certain level.
It will evolve into obesity when it is worthwhile
.
According to the "Chinese National Health and Nutrition Big Data Report", China has 507 million people with overweight and obesity, ranking first in the world.
Not only that, research in the past ten years has found that obesity can also induce a variety of diseases.
Development occurs, so maintaining a healthy figure is not only for pleasing the eyes, but also to reduce the risk of death
.
Pemvidutide (ALT-801) is a peptide-based GLP-1/glucagon dual receptor agonist, which promotes the conversion of white fat into brown fat in the body to consume energy
.
When it has a synergistic effect with GLP-1, it will have a better effect than using a GLP-1 receptor agonist alone
.
The results of its phase 1 clinical trial showed that after receiving 1.
2 mg, 1.
8 mg, and 2.
4 mg pemvidutide, the weight of obese patients decreased by an average of 4.
9%, 10.
3%, and 9.
0%, respectively
.
It is worth noting that in the patient group who received 1.
8 mg of pemvidutide, 55% of the patients lost more than 10% of their body weight, and all patients lost more than 5% of their body weight
.
The weight loss of patients receiving different doses of pemvidutide is more important, the previous studies have shown that pemvidutide can be injected once a week to make the medication more convenient for patients
.
Not only that, the safety of the drug is good, there are no serious treatment-related adverse events, and there are no reports of termination of the trial due to adverse events
.
In the future, it is expected that this new type of weight loss therapy can solve the problems of obese patients
.
In order to facilitate you to continue to receive our articles, you are welcome to set us as a "star" so that you can see our news in the future
.
End reference materials: [1]https://ir.
altimmune.
com/news-releases/news-release-details/altimmune-announces-positive-results-12-week-phase-1-clinical Heavyweight: This kind of malignant tumor with the highest fatality rate may usher in the era of precision treatment.
Hot text generates hundreds of billions of revenue in 6 months.
Why is mRNA such a "god"? Hot article latest! The "Patient Zero" of the new crown in the United States has a high probability of appearing in the hot article Cell sub-news around September 2019: Create another miracle of life! Scientists use pluripotent stem cells to successfully cultivate artificial sperm, which can produce healthy offspring.
AJCN: To live longer, eat beans often! Long-term consumption of soybean diet can make the brain "more agile".
Medical immunotherapy | Biosimilars | Vaccines | Resistance | Drug targets | Healthy life | Pharmaceutical News | Drug inventory | | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anti-cancer Drugs | 4+7 Volume Procurement | Consumables | Record-filing System | Registrant System | Healthy China | New Edition Essential Medicine List | AI Medical Devices | Telemedicine | Same-share non-equity market/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market |
